A GLOBAL LEADER IN CANNABIS GENETICS

“IF YOU WANT IT – WE CAN MAKE IT”

WE HAVE AN EXTREMELY VALUABLE AND EXPANDING LIBRARY

OF UNIQUE AND AWARD-WINNING CANNABIS STRAINS

THROUGH OUR GROUNDBREAKING TECHNOLOGIES, WE ARE POISED TO CREATE A WEALTH OF CUSTOM BESPOKE PRODUCT OPPORTUNITIES

WE HAVE A UNIQUE BUSINESS STRATEGY TO EXPAND OUR OPERATIONS INTO NEW MARKETS

OUR ADVANTAGE

MMGenetics can offer our clients a unique menu of cannabinoids and terpenes.

With over 30 years of research experience in genetic architecture, we are experts in minor cannabinoids with our focus on pushing the boundaries in research and development


Exact chemistry profiles reduce cost in downstream processing


Our genetic library provides minor cannabinoid and terpenes in exclusive ratios designed to provide a bespoke and accurate composition

CREATING GENETIC EXCELLENCE

IP

Intellectual property includes over 100 genetic lines with lineage traceability

100%

We have achieved a 100% germination rate for our established seed lines

Robust

Robust response to multiple propagation environments including indoor, greenhouse and outdoor cultivation

Winners

Multiple awards including six Spannabis Champions Cups* for CBD strains

PROVEN SUCCESS CD-1

Highest known consistent ratios in a CBD-rich seed strain ever created in Europe to date


Additional 12 elite strains using CD-1 as a parent


Independent lab assessments lead selection


Two dominant phenotypes allow flexibility


Grown in a GMP facility, cannabinoid levels remain high and consistent

IMPRESSIVE TRACK RECORD

Winner of 6 Spannabis Champions Cups


Our team of genetics experts, collectively, have won 50+ cannabis-related awards

(*) The Spannabis Champions Cup is the most recognised breeders award in Europe. In 2017, MMG was the first seed company in history to claim three cups concurrently.

EXPERT ADVISORY BOARD

Owen Van Cauwenberghe, PhD – Founding partner, President and COO of Bio Therapeutic Molecules Inc., Adjunct Associate Professor in the Waterloo School of Pharmacy, former Chief Research Officer at AgMedica Bioscience Inc., former Director at Accucaps Industries Ltd. and former Director, Principal Research Scientist at Eli Lilly Canada. Previously a member of the Board of Directors at MedC Biopharma.

Barry Shelp, PhD – Founding partner, Director of Bio Therapeutic Molecules Inc., Professor Emeritus and Adjunct Professor, University of Guelph, Co-founder and Director of Current Water Technologies Inc., former advisor to AgMedica Bioscience Inc. Primary research focused on various strategies concerned with developing abiotic and biotic stress resistance in plants using genetic engineering strategies. In 2015 was awarded the Gold Medal by the Canadian Society for Plant Biologists for outstanding published contributions and for distinguished service to plant biology.

Vince Quiquero, PhD – Founding partner, Director of Bio Therapeutic Molecules Inc., former Chief Scientific Officer at AgMedica Bioscience Inc., former Executive Vice President of Research and Development at Accucaps Industries Ltd., former Associate Director at Eli Lilly Canada and formerly held various positions of increasing responsibility at GlaxoSmithKline. Previously a member of the Board of Directors at Herbolea Biotech.

Adrian Burruezo – PhD Genetics and Plant Breeding ETSIAMN, Universitat Politècnica de València COMAV Institute. More than 20 years of experience in plant breeding and genetics. Enhancement of quality traits (bioactive compounds, antioxidants, volatiles, aroma, taste and flavour compounds), phylogenetic studies incrop species, genome wide association, gene expression, use of germplasm diversity for adaptation to low input conditions, organic agriculture and consumers preferences

TESTIMONIALS

In MMG, Agmedica has found an exceptional partner driven by the optimal mix of passion, expertise and quality one needs to compete and prosper in the new cannabis economy. Their knowledge of genetics, breeding and strain slection has definitely provided Agmedica a distinct advantage in both the medicinal and recreational space.

Trevor Henry

Ag Medica CEO

From day one, MMG has been great to work with, they have an incredible and knowledgeable team that has always gone above and beyond to help us. They have provided great suggestions for new strains and marketplace perspective. Their latest strain that we have grown has done incredibly well in our indoor facility, large firm dense flowers with great trichomes. We are very happy to be working together with MMG and look forward to a long relationship together.

Jeremy Buitenhuis

Ag Medica COO

As a company that develops precisely formulated medications from cannabis, we can only with the best in the industry. MMGenetics meets reliability, quality, responsiveness and consistency with precision. Ben, Ricardo and Seve run a superb company exhibiting the highest of our industry’s standards.

Avi Drori

Chairman and Interim CEO MedC

thin

EXECUTIVE TEAM

Benedict Denman

Founder  / Chief  Strategy

An experienced cannabis private investor, who has been investing in European legal cannabis start ups since 2014 after a number of years spent researching and networking across the sector. He brings knowledge, experience and a strong network in Europe and globally.

Severiano Aznarez

Founder / Chief Research Officer

+30 years breeding experience. He worked as Master Breeder and R&D researcher for the most important Spanish, and Dutch Seed Banks leaders.Winner of more than 20 cannabis awards including Spannabis Champions Cup.

Ricardo Gili

CEO

Hands-on entrepreneur, and business leader, with more than 15 years of experience in Corporate Development and Strategy functions in large European Corporations. Senior leadership roles in International Market development.Founder of Meteo 273º , first worldwide Social Media Network focused on meteorology.

CONTACT

C/Paseo de la Castellana 163

28046, Madrid, Spain


+34 600 43 08 57

info@MMGenetics.com